Targeting the neuroimmune axis in glioblastoma: emerging strategies for precision immunotherapy
Glioblastoma (GBM) is the most common and fatal primary brain malignancy in adults, and therapeutic gains have been modest despite multimodal standard care. Immunotherapy offers a promising alternative, yet its performance in GBM is constrained by a pr…